Related Experiment Videos
Somatostatinoma syndrome: does a clinical entity exist?
Acta Endocrinologica
|January 1, 1983
Summary
Patients with somatostatinomas, tumors secreting somatostatin, may not display predictable symptoms. These neuroendocrine tumors can present with varied clinical and biochemical features, complicating diagnosis.
Area of Science:
- Endocrinology
- Oncology
- Gastroenterology
Background:
- Somatostatinomas are rare neuroendocrine tumors.
- Hypersomatostatinaemia can result from these tumors, but clinical manifestations vary.
- Understanding the diverse presentations is crucial for diagnosis.
Observation:
- Two patients with somatostatin-secreting tumors and elevated somatostatin-like immunoreactivity (SLIR) were studied.
- One patient presented with diabetes, flushing, labile blood pressure, and diarrhea, with elevated calcitonin, prostaglandin E2 (PGE2), and pancreatic polypeptide (PP).
- The second patient had an SLIR-secreting duodenal tumor with elevated SLIR but lacked typical symptoms.
Findings:
- Tumor immunocytochemistry revealed mixed-cell populations expressing somatostatin, calcitonin, PGE2, and PP in the first patient.
- The second patient's tumor showed somatostatin and calcitonin expression.
- Elevated SLIR levels, even post-tolbutamide, were observed in both, but clinical correlation was inconsistent.
Implications:
- Somatostatinomas do not always present with a predictable clinical syndrome.
- The clinical and biochemical features can mimic other endocrine tumors due to mixed-cell origin.
- Diagnosis requires comprehensive evaluation beyond single hormone overproduction assessment.